한글목차

아시아태평양의 싱글셀 멀티오믹스 시장 규모는 2023년 3억 달러에서 2033년에는 18억 5,000만 달러에 달할 것으로 예상되며, 예측 기간인 2023-2033년 동안 20.00%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다.

이 시장은 대규모 게놈 연구에서 단일 세포 RNA 시퀀싱(Sc-RNA)의 사용 증가, 질병 선별 및 진단을 위해 단일 세포 멀티오믹스 접근법을 사용하는 개인 맞춤형 의료로의 전환, 의약품 개발에서 단일 세포 멀티오믹스 도입 증가 등 다양한 요인에 의해 성장하고 있다, 다양한 요인에 의해 성장하고 있습니다.

아시아태평양(APAC) 지역의 단일세포 다중체학 시장은 몇 가지 중요한 요인으로 인해 괄목할 만한 성장을 보이고 있습니다. 여기에는 지역 전체에서 유전체학 연구에서 단일세포 멀티오믹스 기술의 채택이 증가하고 있다는 점이 포함됩니다. 개인 맞춤형 의료에 대한 관심이 높아짐에 따라 질병을 선별하고 진단하기 위해 단일세포 다중유전체학 접근법을 활용하는 방향으로 전환하고 있습니다. 또한, APAC 지역에서는 의약품 개발 과정에서 단일세포 다중체의학의 적용이 증가하는 추세입니다. 게놈 연구를 지원하는 정부 이니셔티브와 의료 인프라의 발전은 시장 성장에 더욱 기여하고 있습니다. 방대한 인구와 정밀의료에 대한 관심이 높아짐에 따라 APAC의 단일세포 다중체학 시장은 연구기관, 제약사 및 의료 서비스 제공업체에게 질병을 더 잘 이해하고 환자 개개인을 위한 맞춤형 표적 치료법을 개발할 수 있는 유망한 기회를 제공합니다.

이 보고서는 아시아태평양의 싱글셀 멀티오믹스 시장에 대해 조사했으며, 시장 개요, 국가별 동향, 시장 진출 기업 프로파일 등의 정보를 제공합니다.

목차

주요 요약

조사 범위

제1장 시장

• 시장 전망
• 시장 개요
• 업계 전망
• COVID-19의 영향
• 비즈니스 역학

제2장 싱글셀 멀티오믹스 시장(지역별)

• 아시아태평양

제3장 시장 - 경쟁 벤치마킹과 기업 개요

• 경쟁 벤치마킹
  • 주요 전략과 전개
  • 시장 점유율 분석
  • 성장 점유율 분석
  • 기업 비주얼 그래픽스
  • 멀티오믹스 에코시스템 활약 기업
• 기업 개요
  • BGI Group
  • Shilps Sciences
  • Takara Bio Inc.

영문목차

The Asia-Pacific Single-Cell Multi Omics Market Expected to Reach $1.85 Billion by 2033

Introduction to Asia-Pacific Single-Cell Multi-Omics Market

The Asia-Pacific single-cell multi-omics market is projected to reach $1.85 billion by 2033 from $0.30 billion in 2023, growing at a CAGR of 20.00% during the forecast period 2023-2033. The market is growing owing to various factors, such as the rising use of single-cell RNA sequencing (Sc-RNA) in large-scale genomics studies, a transition toward personalized medicine employing the single-cell multi-omics approach for disease screening and diagnostics, and increased uptake of single-cell multi-omics in drug development.

Market Introduction

The Asia-Pacific (APAC) single-cell multi-omics market is experiencing notable growth, driven by several key factors. This includes the increasing adoption of single-cell multi-omics technologies in genomics studies across the region. As personalized medicine gains prominence, there's a growing shift towards utilizing single-cell multi-omics approaches for disease screening and diagnostics. Moreover, the APAC region is witnessing a rising trend in the application of single-cell multi-omics in drug development processes. Government initiatives supporting genomic research and advancements in healthcare infrastructure further contribute to market growth. With a vast population and increasing focus on precision medicine, the APAC single-cell multi-omics market presents promising opportunities for research institutions, pharmaceutical companies, and healthcare providers to enhance understanding of diseases and develop targeted therapies tailored to individual patients.

Market Segmentation:

Segmentation 1: by Country

• China
• Japan
• India
• Australia
• Singapore
• Rest-of-Asia-Pacific

How can this report add value to an organization?

Growth/Marketing Strategy: The APAC single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.

Competitive Strategy: The APAC single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in various applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

• BGI Group
• Shilps Sciences
• Takara Bio Inc.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
• 1.2 Market Overview
  • 1.2.1 Key Findings
  • 1.2.2 Current Market Scenario
    • 1.2.2.1 For Researchers
    • 1.2.2.2 For Diagnostics
• 1.3 Industry Outlook
  • 1.3.1 Regulatory Framework
  • 1.3.2 Patent Analysis
    • 1.3.2.1 Awaited Technological Developments
    • 1.3.2.2 Patent Filing Trend (by Country)
    • 1.3.2.3 Patent Filing Trend (by Year)
  • 1.3.3 Key Trends
    • 1.3.3.1 Advancements in Imaging Techniques for Single-Cell Sequencing
    • 1.3.3.2 Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
    • 1.3.3.3 Increased Development of Advanced Solution Based on Single-Cell Technology
  • 1.3.4 Opportunity Assessment
  • 1.3.5 Product Benchmarking
  • 1.3.6 Clinical Trials
• 1.4 COVID-19 Impact
  • 1.4.1 Pre-COVID-19
  • 1.4.2 During COVID-19
  • 1.4.3 Post COVID-19
• 1.5 Business Dynamics
  • 1.5.1 Impact Analysis
  • 1.5.2 Business Drivers
    • 1.5.2.1 Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
    • 1.5.2.2 Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
    • 1.5.2.3 Increasing Use of Single-Cell Multi-Omics for Drug Development
    • 1.5.2.4 Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
  • 1.5.3 Business Restraints
    • 1.5.3.1 High Cost of Single-Cell Analysis and Sequencing
    • 1.5.3.2 Limited Availability of Large Online Data Storage and Analysis Platforms
  • 1.5.4 Business Opportunities
    • 1.5.4.1 Expansion into New Research Applications, Such as Single-Cell Metabolomics
    • 1.5.4.2 Increasing Adoption of Genomic-Based Medicine in Emerging Nations

2 Single-Cell Multi-Omics Market (by Region)

• 2.1 Asia-Pacific
  • 2.1.1 Key Findings and Opportunity Assessment
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Sizing and Forecast Analysis
    • 2.1.3.1 Asia-Pacific Single-Cell Multi-Omics Market (by Country)
      • 2.1.3.1.1 China
      • 2.1.3.1.2 Japan
      • 2.1.3.1.3 India
      • 2.1.3.1.4 Singapore
      • 2.1.3.1.5 Australia
      • 2.1.3.1.6 Rest-of-Asia-Pacific

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 New Offerings
    • 3.1.1.3 Mergers and Acquisitions
    • 3.1.1.4 Partnership, Collaboration, and Business Expansion
  • 3.1.2 Market Share Analysis
  • 3.1.3 Growth Share Analysis
    • 3.1.3.1 By Application
    • 3.1.3.2 By Omics Type
    • 3.1.3.3 By Product Type
  • 3.1.4 Visual Graphics of the Companies
  • 3.1.5 Multi-Omics Ecosystem Active Players
• 3.2 Company Profiles
  • 3.2.1 BGI Group
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Role of BGI Group in the Single-Cell Multi-Omics Market
    • 3.2.1.3 Financials
    • 3.2.1.4 Analyst Perspective
  • 3.2.2 Shilps Sciences
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Role of Shilps Sciences in the Single-Cell Multi-Omics Market
    • 3.2.2.3 Analyst Perspective
  • 3.2.3 Takara Bio Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Role of Takara Bio Inc. in the Single-Cell Multi-Omics Market
    • 3.2.3.3 Financials
    • 3.2.3.4 Analyst Perspective